Industry veterans of managed care solutions, healthcare biotech, and transplant created Emerging Therapy Solutions® to help healthcare payers – including reinsurance and stop-loss payers, health plans and self-funded employers – manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.
To anticipate and understand what lies ahead for medical and underwriting services teams, we proactively monitor the latest developments for existing therapies and the clinical trial pipeline for near-term approvals. We curate and maintain a comprehensive Knowledge Center with extensive clinical education and data resources on these therapies and the rare and complex conditions being treated. We engage independent physician experts on standards of care for diagnosis, treatment, and review.
Emerging Therapy Solutions was originally founded in 2018 to offer expert services to help payers and other risk-bearing entities prepare for the accelerating growth in cell and gene therapy. In 2020, Emerging Therapy Solutions acquired LifeTrac. LifeTrac was founded in 1988 to offer solutions that focus on high-cost, low-frequency medical events. The LifeTrac team brings over 30 years of experience in bone marrow and solid organ transplants, plus provider relationships and agreements, to complement Emerging Therapy Solutions’ expertise in cell and gene therapies. The integrated company became Emerging Therapy Solutions (ETS) in 2021.
We provide trusted insight and expert services to payers, so they can maximize value for people in need of the newest complex and costly therapies.
You must be logged in to post a comment.